A Retrospective study to evaluate the safety and efficacy of Amifostine in preventing chemoradiotherapy-related Esophagitis in Small cell lung cancer patients
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2018
Price : $35 *
At a glance
- Drugs Amifostine (Primary)
- Indications Radiation injuries
- Focus Adverse reactions; Therapeutic Use
- 05 Oct 2018 New trial record
- 27 Sep 2018 Results presented in the Cumberland Pharmaceuticals media release.
- 27 Sep 2018 According to a Cumberland Pharmaceuticals media release, the principal investigator of the trial is Ariel E Pollock M.D, Icahn School of Medicine at Mt. Sinai, New York.